Given that platelets are capable of regulating inflammation and immunity [9, 73], the composition and effect of CRP and FFV PEVs on different cancer cell types warrant further investigation in the future, e.g. using engineered CRP PEVs and FFV PEVs in drug delivery. The gene discussed is CRP; the disease is cancer.